Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company headquartered in Ann Arbor, Michigan. The company is dedicated to discovering, developing, and commercializing innovative oral therapies aimed at reducing elevated levels of low-density lipoprotein cholesterol (LDL-C) and mitigating cardiovascular risk. Its mission is to bring new medicines to market that address unmet needs of patients and healthcare professionals in cardiovascular disease management.

Esperion's primary marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets. These are oral, once-daily, non-statin medicines approved for the treatment of primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD), in adults who require additional LDL-C lowering. The company also markets these products in Europe under the brand names NILEMDO and NUSTENDI, respectively.

Sheldon Koenig serves as the President and Chief Executive Officer of Esperion Therapeutics. In a significant recent development, Esperion announced on May 1, 2026, that it has entered into a definitive agreement to be acquired by ARCHIMED, a healthcare investment firm. The transaction, valued at up to $1.1 billion, will provide shareholders with $3.16 per share in cash plus contingent milestone payments. This acquisition is expected to close in the third quarter of 2026, after which Esperion will become a privately held company and its common stock will no longer be listed on Nasdaq. Additionally, on April 2, 2026, Esperion completed the acquisition of Corstasis Therapeutics, adding Enbumyst™ (bumetanide nasal spray) to its cardiovascular portfolio.